2015
Nivolumab in NSCLC: latest evidence and clinical potential
Sundar R, Cho B, Brahmer J, Soo R. Nivolumab in NSCLC: latest evidence and clinical potential. Therapeutic Advances In Medical Oncology 2015, 7: 85-96. PMID: 25755681, PMCID: PMC4346216, DOI: 10.1177/1758834014567470.Peer-Reviewed Original ResearchNon-small cell lung cancerStudy of nivolumabImmune checkpoint modulatorsPD-1 inhibitorsCell lung cancerMolecular targeted therapyTreatment of patientsEarly phase studiesHost immune responseUnresectable melanomaPD-1Checkpoint modulatorsSolid tumorsNivolumabEvading host immune responsesImmune modulationLung cancerImmune responseClinical potentialImmune systemLigand pathwayRegulatory approvalTumorPatientsChemotherapy
2014
Immunotherapy in the treatment of non-small cell lung cancer
Sundar R, Soong R, Cho B, Brahmer J, Soo R. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014, 85: 101-109. PMID: 24880938, PMCID: PMC4332778, DOI: 10.1016/j.lungcan.2014.05.005.Peer-Reviewed Original ResearchConceptsImmune response to tumorsTreatment of non-small cell lung cancerNon-small cell lung cancerProlonged clinical responsesImmune checkpoint modulatorsImmune checkpoint pathwaysPD-L1 inhibitorsResponse to tumorsCell lung cancerCTLA-4PD-1PD-L1Tolerable toxicityTumor immunosurveillanceCheckpoint modulatorsCo-stimulatoryCo-inhibitoryClinical responseImmunotherapeutic agentsPredictive biomarkersImmune destructionLung cancerTreatment selectionImmune systemInhibitory molecules